# A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

> **NCT06406465** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (estimated)

## Conditions studied

- Carcinoma, Neuroendocrine
- Tumor, Neuroendocrine
- Tumors, Neuroendocrine
- Neuroendocrine; Carcinoma
- Small Cell; Receptors

## Interventions

- **DRUG:** Belinostat
- **DRUG:** Cisplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT06406465
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2027-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06406465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06406465, "A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06406465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*